Envoy Medical to Present at the LD Micro Main Event XVII
Envoy Medical (NASDAQ: COCH), a hearing health company specializing in fully implanted hearing systems, announced that CFO David R. Wells will deliver a corporate overview at the LD Micro Main Event XVII. The presentation is scheduled for Tuesday, October 29, 2024, at 12:00 PM Pacific Time at the Luxe Sunset Boulevard Hotel in Los Angeles. The conference runs from October 28-30, 2024. Registered investors can watch the presentation online and schedule one-on-one meetings with Mr. Wells during the event.
Envoy Medical (NASDAQ: COCH), un'azienda specializzata nella salute uditiva con sistemi impiantati completamente, ha annunciato che il CFO David R. Wells presenterà una panoramica aziendale al LD Micro Main Event XVII. La presentazione è prevista per martedì 29 ottobre 2024, alle 12:00 ore del Pacifico, presso il Luxe Sunset Boulevard Hotel di Los Angeles. La conferenza si svolgerà dal 28 al 30 ottobre 2024. Gli investitori registrati possono seguire la presentazione online e programmare incontri individuali con il signor Wells durante l'evento.
Envoy Medical (NASDAQ: COCH), una empresa de salud auditiva especializada en sistemas auditivos completamente implantados, anunció que el CFO David R. Wells ofrecerá una visión general de la empresa en el LD Micro Main Event XVII. La presentación está programada para el martes 29 de octubre de 2024, a las 12:00 PM, hora del Pacífico, en el Luxe Sunset Boulevard Hotel en Los Ángeles. La conferencia se llevará a cabo del 28 al 30 de octubre de 2024. Los inversores registrados pueden ver la presentación en línea y programar reuniones uno a uno con el Sr. Wells durante el evento.
Envoy Medical (NASDAQ: COCH), 완전Implantable Hearing Systems 전문 청각 건강 회사는 CFO David R. Wells가 LD Micro Main Event XVII에서 기업 개요를 발표할 것임을 발표했습니다. 발표는 2024년 10월 29일 화요일 오후 12시 (태평양 표준시) 로스앤젤레스의 Luxe Sunset Boulevard Hotel에서 예정되어 있습니다. 컨퍼런스는 2024년 10월 28일부터 30일까지 진행됩니다. 등록된 투자자는 온라인으로 발표를 시청하고 행사 중에 Wells 씨와 일대일 미팅을 예약할 수 있습니다.
Envoy Medical (NASDAQ: COCH), une entreprise de santé auditive spécialisée dans les systèmes auditifs entièrement implantés, a annoncé que le CFO David R. Wells fera une vue d'ensemble de l'entreprise lors du LD Micro Main Event XVII. La présentation est prévue pour le mardi 29 octobre 2024, à 12h00, heure du Pacifique, à l'hôtel Luxe Sunset Boulevard à Los Angeles. La conférence se déroulera du 28 au 30 octobre 2024. Les investisseurs enregistrés peuvent suivre la présentation en ligne et programmer des réunions individuelles avec M. Wells pendant l'événement.
Envoy Medical (NASDAQ: COCH), ein Unternehmen für Hörgesundheit, das sich auf vollständig implantierte Hörsysteme spezialisiert hat, kündigte an, dass CFO David R. Wells einen Unternehmensüberblick auf dem LD Micro Main Event XVII präsentieren wird. Die Präsentation ist für Dienstag, den 29. Oktober 2024, um 12:00 Uhr pazifischer Zeit im Luxe Sunset Boulevard Hotel in Los Angeles geplant. Die Konferenz findet vom 28. bis 30. Oktober 2024 statt. Registrierte Investoren können die Präsentation online verfolgen und während der Veranstaltung Einzelgespräche mit Herrn Wells vereinbaren.
- None.
- None.
WHITE BEAR LAKE, Minnesota, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. (“Envoy Medical”) (NASDAQ: “COCH”), a hearing health company focused on fully implanted hearing systems, today announced that David R. Wells, Chief Financial Officer, will present a corporate overview at the LD Micro Main Event XVII. The conference is being held on October 28 – 30, 2024 at the Luxe Sunset Boulevard Hotel in Los Angeles.
Event: LD Micro Main Event XVII
Presentation Date: Tuesday, October 29, 2024
Time: 12:00 PM Pacific Time
Register to watch presentation: https://me24.sequireevents.com/
Mr. Wells will be available for one-on-one meetings with registered investors of the conference.
About the Esteem® Fully Implanted Active Middle Ear Implant (FI-AMEI)
The Esteem fully implanted active middle ear implant (FI-AMEI) is the only FDA-approved, fully implanted* hearing device for adults diagnosed with moderate to severe sensorineural hearing loss allowing for 24/7 hearing capability using the ear’s natural anatomy. The Esteem FI-AMEI hearing implant is invisible and requires no externally worn components and nothing is placed in the ear canal for it to function. Unlike hearing aids, you never put it on or take it off. You can’t lose it. You don’t clean it. The Esteem FI-AMEI hearing implant offers true 24/7 hearing.
*Once activated, the external Esteem FI-AMEI Personal Programmer is not required for daily use.
Important safety information for the Esteem FI-AMEI can be found at: https://www.envoymedical.com/safety-information.
About the Fully Implanted Acclaim® Cochlear Implant
We believe the fully implanted Acclaim Cochlear Implant (“Acclaim CI”) will be a first-of-its-kind fully implanted cochlear implant. Envoy Medical’s fully implanted technology includes a sensor designed to leverage the natural anatomy of the ear instead of a microphone to capture sound.
The Acclaim CI is designed to address severe to profound sensorineural hearing loss that is not adequately addressed by hearing aids. The Acclaim CI is expected to be indicated for adults who have been deemed adequate candidates by a qualified physician.
The Acclaim Cochlear Implant received the Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) in 2019. We believe the Acclaim CI was the first hearing-focused device to receive Breakthrough Device Designation.
CAUTION The fully implanted Acclaim Cochlear Implant is an investigational device. Limited by Federal (or United States) law to investigational use.
Additional Information and Where to Find It
Copies of the documents filed by Envoy Medical with the SEC may be obtained free of charge at the SEC’s website at www.sec.gov.
Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-Looking statements may be identified by the use of words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “will,” “expect,” “anticipate,” “believe,” “seek,” “target” or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters, but the absence of these words does not mean that a statement is not forward-looking. Such statements may include, but are not limited to, statements regarding the expectations of Envoy Medical concerning the outlook for its business, productivity, plans and goals for future operational improvements and capital investments; the future market trading performance of our Class A Common Stock; the future size of the market for our products; the performance and benefits of our products in comparison to competitor products; the benefits of intellectual property developed by Envoy; the potential for passage of legislation related to reimbursement for active middle ear hearing devices; the impact that such proposed legislation might have on the hearing health market, reimbursement for the Esteem FI-AMEI device, and the Envoy Medical business; and future market conditions or economic performance, as well as any information concerning possible or assumed future operations of Envoy Medical. The forward-looking statements contained in this press release reflect Envoy Medical’s current views about future events and are subject to numerous known and unknown risks, uncertainties, assumptions and changes in circumstances that may cause its actual results to differ significantly from those expressed in any forward-looking statement. Envoy Medical does not guarantee that the events described will happen as described (or that they will happen at all). These forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to changes in the market price of shares of Envoy Medical’s Class A Common Stock; changes in or removal of Envoy Medical’s shares inclusion in any index; Envoy Medical’s success in retaining or recruiting, or changes required in, its officers, key employees or directors; unpredictability in the medical device industry, the regulatory process to approve medical devices, and the clinical development process of Envoy Medical products; competition in the medical device industry, and the failure to introduce new products and services in a timely manner or at competitive prices to compete successfully against competitors; disruptions in relationships with Envoy Medical’s suppliers, or disruptions in Envoy Medical’s own production capabilities for some of the key components and materials of its products; changes in the need for capital and the availability of financing and capital to fund these needs; changes in interest rates or rates of inflation; legal, regulatory and other proceedings could be costly and time-consuming to defend; changes in applicable laws or regulations, or the application thereof on Envoy Medical; a loss of any of Envoy Medical’s key intellectual property rights or failure to adequately protect intellectual property rights; the effects of catastrophic events, including war, terrorism and other international conflicts; and other risks and uncertainties set forth in the section entitled “Risk Factors” and “Cautionary Note Regarding Forward Looking Statements” in the Annual Report on Form 10-K filed by Envoy Medical on April 1, 2024, and in other reports Envoy Medical files, with the SEC. If any of these risks materialize or Envoy Medical’s assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. While forward-looking statements reflect Envoy Medical’s good faith beliefs, they are not guarantees of future performance. Envoy Medical disclaims any obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, new information, data or methods, future events or other changes after the date of this press release, except as required by applicable law. You should not place undue reliance on any forward-looking statements, which are based only on information currently available to Envoy Medical.
###
Investor Contact:
CORE IR
516-222-2560
investorrelations@envoymedical.com
FAQ
When will Envoy Medical (COCH) present at the LD Micro Main Event XVII?
Where is the LD Micro Main Event XVII conference being held?
Who will represent Envoy Medical (COCH) at the LD Micro Main Event XVII?